Compositions and Method for Multimodal Imaging
a multi-modal imaging and composition technology, applied in the field of medical imaging, can solve the problems of limited size, no available non-invasive methods for distinguishing between lymph nodes, and used in image-guidance applications, and achieve the effect of prolonging contrast imaging
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
[0063]Radionuclide imaging in accordance with the method and composition described above may involve incorporation of derivatized lipids that can chelate the radiometals 99mTc and 111In for SPECT imaging and 64Cu for PET. These radionuclides are readily available from a generator system (99Mo / 99mTc; Bristol-Myers-Squibb) or can be purchased from MDS-Nordion Inc. (111In and 64Cu). PE lipid can be derivatized at the headgroup with HYNIC for labeling with 99mTc; DTPA for labeling with 111In; or with TETA for labeling with 64Cu. These bifunctional chelators are all commercially available from Macrocyclics Inc. Unilamellar liposomes can be prepared using established methods based on high-pressure extrusion and sonication. The labeled liposomes can be formed from the newly synthesized chelator-modified PE and the mixture of lipids originally employed in the liposome formulation. Following preparation, liposomes containing the chelator-modified PE lipid can be incubated with 99mTc, 111In, ...
example 2
Methods and Materials
Materials
[0064]The components of liposomes: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC, M.W. 734), Cholesterol (CH, M.W. 387) and 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol)2000] (PEG2000DSPE, M.W. 2774) were purchased from Northern Lipids Inc. (Vancouver, British Columbia, Canada). The CT signal modifying agent, Omnipaque® was obtained from Nycomed Imaging AS, Oslo, Norway. Omnipaque® (300 mg / mL of Iodine) contains iohexol (M.W. 821.14), an iodinated, water-soluble, non-ionic monomeric contrast medium. The MR signal modifying agent used was ProHance® from Bracco Diagnostics Inc. (Princeton, N.J., USA). ProHance® (78.6 mg / mL of gadolinium) contains gadoteridol (M.W. 558.7), a non-ionic gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
Preparation of Liposome Formulations
[0065]Lipid mixtures (200 mmol / L) of DPPC, cholesterol and PEG2000DSPE in 55:40:5 percent mole ratios were dissol...
example 3
Materials
[0086]The following lipids: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC, M.W. 734), Cholesterol (CH, M.W. 387) and 1,2- Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol)2000] (PEG2000DSPE, M.W. 2774) were purchased from Northern Lipids Inc. (Vancouver, British Columbia, Canada). Omnipaque® was obtained from Nycomed Imaging AS, Oslo, Norway. Omnipaque® (300 mg / mL of iodine) contains iohexol (M.W. 821.14), an iodinated, water-soluble, non-ionic monomeric contrast medium. ProHance® from Bracco Diagnostics Inc. (Princeton, N.J., USA). ProHance® (78.6 mg / mL of gadolinium) contains gadoteridol (M.W. 558.7), a non-ionic gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
Liposome Preparation
[0087]200 mmol / L of the DPPC, cholesterol and PEG2000DSPE (55:40:5 mole ratio) mixture was dissolved in ethanol at 70° C. and then hydrated with Omnipaque® and Prohance®. The total ethanol content was 10%vol. The resulting mul...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com